Divyashakti Q4 FY26 Results: Loss Rs 2.8 Cr

Divyashakti Q4 FY26 results were declared on May 24, 2026. The company reported net loss of Rs 2.8 crore for the quarter ended March 31, 2026, down 660.0% YoY compared to Rs 0.5 crore in Q4 FY25. Revenue from operations was Rs 0.5 crore, down 95.8% YoY. Results are on a Standalone basis. Divyashakti is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Divyashakti Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 0.5 crore	Rs 12 crore	-95.8%
Net Loss	2.8	0.5	-660.0%
Basis	Standalone

Note: Q4 FY26 revenue collapse and margin erosion signal deep operational distress. Net loss Rs 2.8 crore. Verify from BSE/NSE audited filings before investment decisions.

Divyashakti Q4 FY26 Performance Analysis

The Divyashakti Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter reflects near-term profitability challenges. Divyashakti operates in the Pharmaceuticals sector, supported by India’s GDP growth above 6.5% in FY26.

Revenue of Rs 0.5 crore was down 95.8% YoY. Revenue moderation reflects near-term demand headwinds.

Screen the best stocks on the Univest Screener.

Key Factors Driving Divyashakti Q4 FY26 Results

Revenue and Business Performance

Revenue of Rs 0.5 crore in Divyashakti Q4 FY26 was down 95.8% YoY. Revenue pressure reflects near-term demand headwinds in the Pharmaceuticals market. The January to March quarter is the fiscal year-end period characterised by strong order execution cycles.

Profitability and Margin Trends

The the business net loss of Rs 2.8 crore down 660.0% YoY. The net loss reflects ongoing operational challenges. Cost discipline and revenue recovery remain FY27 priorities.

India Macro Environment

India’s macro environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement, and capital allocation will be key investor watchpoints. Returning to profitability through operational improvements remains the key FY27 objective.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.